Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 11,430,000 shares of its common stock at a price to the public of $35.00 per share.
November 10, 2:55 AM
U.S. stocks closed lower on Wednesday, with the Dow Jones dipping more than 600 points. Here is the list of some big stocks recording losses in the previous session.
November 7, 1:22 PM
Natera (NASDAQ:NTRA) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Natera will report an earnings per share (EPS) of $-1.44.
September 12, 9:29 AM
Data from the largest real-world MRD study to date in resectable colorectal cancer reinforces the findings from the recent CIRCULATE-Japan study AUSTIN, Texas, Sept. 12, 2022 /PRNewswire/ -- Natera,
August 25, 5:27 AM
Credit Suisse analyst Dan Leonard initiates coverage on Natera (NASDAQ:NTRA) with a Outperform rating and announces Price Target of $70.
July 18, 1:42 PM
Natera, Inc. (NASDAQ:NTRA), a leader in personalized genetic testing and diagnostics, today announced that the Federal Circuit Court of Appeals affirmed the Delaware Federal District Court's September
Natera Highlights Trifecta Study; Says Study Establishes New Validation Standard For dd-cfDNA In Kidney Transplant Rejection With Largest Prospective, Multisite, Fully Biopsy-Matched Study
June 29, 11:58 AM
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of a manuscript in a leading journal in the organ transplant space, Transplantation, validating